Compare FULC & PPHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FULC | PPHC |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.4M | 305.8M |
| IPO Year | 2019 | 2025 |
| Metric | FULC | PPHC |
|---|---|---|
| Price | $3.77 | $11.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $3.67 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 1.2M | 159.9K |
| Earning Date | 10-28-2026 | 08-10-2026 |
| Dividend Yield | N/A | ★ 3.27% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $186,541,000.00 |
| Revenue This Year | N/A | $15.06 |
| Revenue Next Year | N/A | $9.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.72 |
| 52 Week Low | $2.83 | $7.01 |
| 52 Week High | $15.74 | $15.15 |
| Indicator | FULC | PPHC |
|---|---|---|
| Relative Strength Index (RSI) | 51.35 | 50.44 |
| Support Level | $3.75 | $9.79 |
| Resistance Level | $3.91 | $11.78 |
| Average True Range (ATR) | 0.07 | 0.71 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 52.50 | 44.83 |
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Public Policy Holding Co Inc operates as a advisory firm. The company also operates a portfolio of independent firms that offer public affairs, crisis management, lobbying, and advocacy services on behalf of the corporate, trade association, and non-profit client organisations. Its business comprises of three reporting segments - Government Relations Consulting, Corporate Communications & Public Affairs Consulting and Compliance and Insights Services.